169 related articles for article (PubMed ID: 32972410)
1. Effects of doxorubicin associated with amniotic membrane stem cells in the treatment of canine inflammatory breast carcinoma (IPC-366) cells.
Borghesi J; Caceres S; Mario LC; Alonso-Diez A; Silveira Rabelo AC; Illera MJ; Silvan G; Miglino MA; Favaron PO; Carreira ACO; Illera JC
BMC Vet Res; 2020 Sep; 16(1):353. PubMed ID: 32972410
[TBL] [Abstract][Full Text] [Related]
2. Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity.
Bamodu OA; Huang WC; Tzeng DT; Wu A; Wang LS; Yeh CT; Chao TY
Cancer Lett; 2015 Aug; 364(2):125-34. PubMed ID: 25976769
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo effect of flutamide on steroid hormone secretion in canine and human inflammatory breast cancer cell lines.
Caceres S; Monsalve B; Peña L; de Andres PJ; Alonso-Diez A; Illera MJ; Woodward WA; Reuben JM; Silvan G; Illera JC
Vet Comp Oncol; 2018 Mar; 16(1):148-158. PubMed ID: 28589573
[TBL] [Abstract][Full Text] [Related]
4. Synergistic growth inhibitory effect of deracoxib with doxorubicin against a canine mammary tumor cell line, CMT-U27.
Bakirel T; Alkan FÜ; Üstüner O; Çinar S; Yildirim F; Erten G; Bakirel U
J Vet Med Sci; 2016 May; 78(4):657-68. PubMed ID: 26822118
[TBL] [Abstract][Full Text] [Related]
5. Cellular Mechanisms Triggered by the Cotreatment of Resveratrol and Doxorubicin in Breast Cancer: A Translational In Vitro-In Silico Model.
Vargas JE; Puga R; Lenz G; Trindade C; Filippi-Chiela E
Oxid Med Cell Longev; 2020; 2020():5432651. PubMed ID: 33204396
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model.
Kratz F; Azab S; Zeisig R; Fichtner I; Warnecke A
Int J Pharm; 2013 Jan; 441(1-2):499-506. PubMed ID: 23149257
[TBL] [Abstract][Full Text] [Related]
7. The methyl donor S-adenosylmethionine potentiates doxorubicin effects on apoptosis of hormone-dependent breast cancer cell lines.
Ilisso CP; Castellano M; Zappavigna S; Lombardi A; Vitale G; Dicitore A; Cacciapuoti G; Caraglia M; Porcelli M
Endocrine; 2015 Sep; 50(1):212-22. PubMed ID: 25577236
[TBL] [Abstract][Full Text] [Related]
8. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
9. Treatment schedule and estrogen receptor-status influence acquisition of doxorubicin resistance in breast cancer cells.
Ponnusamy L; Mahalingaiah PKS; Singh KP
Eur J Pharm Sci; 2017 Jun; 104():424-433. PubMed ID: 28455002
[TBL] [Abstract][Full Text] [Related]
10. Receptors for oestrogen, progesterone and epidermal growth factor in normal and tumorous canine mammary tissues.
Donnay I; Rauïs J; Wouters-Ballman P; Devleeschouwer N; Leclercq G; Verstegen JP
J Reprod Fertil Suppl; 1993; 47():501-12. PubMed ID: 8229969
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D receptor expression in canine mammary gland and relationship with clinicopathological parameters and progesterone/oestrogen receptors.
Sánchez-Céspedes R; Fernández-Martínez MD; Raya A; Pineda C; López I; Millán Y
Vet Comp Oncol; 2018 Mar; 16(1):E185-E193. PubMed ID: 29178579
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional microenvironment confers enhanced sensitivity to doxorubicin by reducing p53-dependent induction of autophagy.
Gomes LR; Vessoni AT; Menck CF
Oncogene; 2015 Oct; 34(42):5329-40. PubMed ID: 25619836
[TBL] [Abstract][Full Text] [Related]
13. Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues.
Millanta F; Calandrella M; Bari G; Niccolini M; Vannozzi I; Poli A
Res Vet Sci; 2005 Dec; 79(3):225-32. PubMed ID: 16054892
[TBL] [Abstract][Full Text] [Related]
14. Aldoxorubicin-loaded nanofibers are cytotoxic for canine mammary carcinoma and osteosarcoma cell lines in vitro: A short communication.
Stokol T; Wan C; Blakely R; Bellat V; Law B
Res Vet Sci; 2020 Feb; 128():86-89. PubMed ID: 31760317
[TBL] [Abstract][Full Text] [Related]
15. Mechanochemically activated doxorubicin nanoparticles in combination with 40 MHz frequency irradiation on A-549 lung carcinoma cells.
Orel VE; Kudryavets YI; Satz S; Bezdenezhnih NA; Danko ML; Khranovskaya NN; Romanov AV; Dzyatkovskaya NN; Burlaka AP
Drug Deliv; 2005; 12(3):171-8. PubMed ID: 16025847
[TBL] [Abstract][Full Text] [Related]
16. Modulation of multidrug resistance P-glycoprotein activity by antiemetic compounds in human doxorubicin-resistant sarcoma cells (MES-SA/Dx-5): implications on cancer therapy.
Angelini A; Conti P; Ciofani G; Cuccurullo F; Di Ilio C
J Biol Regul Homeost Agents; 2013; 27(4):1029-37. PubMed ID: 24382184
[TBL] [Abstract][Full Text] [Related]
17. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors.
Wiebe JP; Zhang G; Welch I; Cadieux-Pitre HA
Breast Cancer Res; 2013 May; 15(3):R38. PubMed ID: 25927181
[TBL] [Abstract][Full Text] [Related]
18. Establishment and characterization of a canine xenograft model of inflammatory mammary carcinoma.
Camacho L; Peña L; González Gil A; Cáceres S; Díez L; Illera JC
Res Vet Sci; 2013 Dec; 95(3):1068-75. PubMed ID: 23972378
[TBL] [Abstract][Full Text] [Related]
19. Tumor slices as a model to evaluate doxorubicin in vitro treatment and expression of trios of genes PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2 in canine mammary gland cancer.
Sobral RA; Honda ST; Katayama ML; Brentani H; Brentani MM; Patrão DF; Folgueira MA
Acta Vet Scand; 2008 Jul; 50(1):27. PubMed ID: 18601734
[TBL] [Abstract][Full Text] [Related]
20. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP
Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
